BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 38078963)

  • 21. Efficacy and safety of immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis of randomized clinical trials.
    Dang S; Zhang S; Zhao J; Li X; Li W
    Cancer Med; 2023 Oct; 12(20):20277-20286. PubMed ID: 37814950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-PD-1/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis.
    Park R; Lopes L; Saeed A
    Clin Transl Oncol; 2021 Jan; 23(1):100-109. PubMed ID: 32495269
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis.
    Qian X; Chen H; Tao Y
    Front Immunol; 2023; 14():1146898. PubMed ID: 37063822
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Maiorano BA; Di Maio M; Cerbone L; Maiello E; Procopio G; Roviello G;
    JAMA Netw Open; 2024 Mar; 7(3):e241215. PubMed ID: 38446479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
    Zhang N; Jiang J; Tang S; Sun G
    Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An investigative meta-analysis on the effectiveness and safety of integrating VEGF/VEGFR inhibitors with PD-1/PD-L1 inhibitors in cases with R/M HNSCC.
    Wang H; Hu L; Zhang F; Fang M; Xu J; Li M; Chen Z
    Oral Oncol; 2024 Jun; 153():106814. PubMed ID: 38714115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
    Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
    Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
    Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
    Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of nutritional indices in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors.
    Miyamoto N; Takenaka Y; Sudo T; Eguchi H; Tanaka H; Fukusumi T; Takemoto N; Suzuki M; Inohara H
    Acta Otolaryngol; 2023 Oct; 143(10):925-930. PubMed ID: 38059478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predicting the treatment outcome of nivolumab in recurrent or metastatic head and neck squamous cell carcinoma: prognostic value of combined performance status and modified Glasgow prognostic score.
    Ueki Y; Takahashi T; Ota H; Shodo R; Yamazaki K; Horii A
    Eur Arch Otorhinolaryngol; 2020 Aug; 277(8):2341-2347. PubMed ID: 32239313
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy.
    Sadeghirad H; Liu N; Monkman J; Ma N; Cheikh BB; Jhaveri N; Tan CW; Warkiani ME; Adams MN; Nguyen Q; Ladwa R; Braubach O; O'Byrne K; Davis M; Hughes BGM; Kulasinghe A
    Front Immunol; 2023; 14():1135489. PubMed ID: 37153589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of blood-based PD-L1 analysis in patients with non-small cell lung cancer undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis.
    Cui Q; Li W; Wang D; Wang S; Yu J
    World J Surg Oncol; 2023 Oct; 21(1):318. PubMed ID: 37821941
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapy.
    Minichsdorfer C; Gleiss A; Aretin MB; Schmidinger M; Fuereder T
    Ann Med; 2022 Dec; 54(1):1339-1349. PubMed ID: 35535695
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blood biomarkers predict outcomes in patients with hepatocellular carcinoma treated with immune checkpoint Inhibitors: A pooled analysis of 44 retrospective sudies.
    Zhang L; Feng J; Kuang T; Chai D; Qiu Z; Deng W; Dong K; Zhao K; Wang W
    Int Immunopharmacol; 2023 May; 118():110019. PubMed ID: 36933492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Update of a prognostic survival model in head and neck squamous cell carcinoma patients treated with immune checkpoint inhibitors using an expansion cohort.
    Issa M; Klamer BG; Mladkova N; Laliotis GI; Karivedu V; Bhateja P; Byington C; Dibs K; Pan X; Chakravarti A; Grecula J; Jhawar SR; Mitchell D; Baliga S; Old M; Carrau RL; Rocco JW; Blakaj DM; Bonomi M
    BMC Cancer; 2022 Jul; 22(1):767. PubMed ID: 35836204
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma.
    Xu X; Li R; Zhang L; Zhu G; Ren D; Wu L; Gong X
    Diagn Pathol; 2021 Nov; 16(1):110. PubMed ID: 34823553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toxicity profiles of immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis.
    Dang S; Li X; Liu H; Zhang S; Li W
    Cancer Med; 2024 Apr; 13(7):e7119. PubMed ID: 38553943
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.
    Poulose JV; Kainickal CT
    World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-naïve tumors with immune checkpoint inhibitors.
    Tosi A; Parisatto B; Menegaldo A; Spinato G; Guido M; Del Mistro A; Bussani R; Zanconati F; Tofanelli M; Tirelli G; Boscolo-Rizzo P; Rosato A
    J Exp Clin Cancer Res; 2022 Sep; 41(1):279. PubMed ID: 36123711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.